Experience with dupilumab in the treatment of chronic rhinosinusitis with nasal polyps

Close metadata

OBJECTIVE

To study the effectiveness of targeted therapy in patients with CRS with nasal polyps and comorbid asthma.

MATERIAL AND METHODS

19 patients selected for biological therapy according to international criteria were studied. The patients were randomly divided into 2 groups. The first group included 10 patients treated with dupilumab. Dupilumab was administered subcutaneously 300 mg every 2 weeks for 24 weeks. Group 2 included 9 patients treated with reslizumab for severe eosinophilic asthma with comorbid CRS with nasal polyps. Reslizumab was administered intravenously 3 mg/kg body weight once every 4 weeks for 24 weeks. These patients constituted the comparison group. Both drugs are used in treatment of eosinophilic inflammation but have different biological targets.

RESULTS

Comparative analysis of the dynamics of the main indicators characterizing the clinical course of CRS with nasal polyps and asthma (SNOT-22, control of asthma symptoms — ACT, the results of SCT of the paranasal sinuses according to the Lund-Mackay score) revealed a positive trend in patients of both groups, more pronounced in patients receiving dupilumab.

CONCLUSION

Changes in CT of the paranasal sinuses, characterized by the Lund-Mackay score, the results of SNOT-22 and ACT are the most demonstrative and can be used to assess the results of treatment with biologics in patients with chronic rhinosinusitis with nasal polyps.

Keywords:

chronic rhinosinusitis with nasal polyps

asthma

dupilumab

reslizumab

Authors:

Boiko N.V.

Rostov State Medical University

ORCID: 0000-0002-1316-5061

Stagnieva I.V.

Rostov State Medical University

ORCID: 0000-0002-2894-2062

Lodochkina O.E.

Rostov State Medical University

ORCID: 0000-0001-7401-0680

Kurbatova N.V.

Southern Federal University

ORCID: 0000-0002-2343-734X

Received:

04.01.2023

Accepted:

11.04.2023

List of references:

Kim IA, Nosulya EV, Ragimova DR. Features of adherence to treatment of patients with chronic rhinosinusitis with nasal polyps. Vestnik otorinolaringologii. 2022;87(1):81-86. (In Russ.). https://doi.org/10.17116/otorino20228701181
Khan A, Vandeplas G, Huynh TMT, Joish VN, L. Mannent L, Tomassen P, Van Zele T, Cardell LO, Arebro J, Olze H, Foerster-Ruhrmann U, Kowalski ML, Olszewska-Ziaber A, Holtappels G, De Ruyck GN, van Drunen C, Mullol J, Hellings PW, Hox V, Toskala E, Scadding G, Lund VJ, Fokkens WJ, Bachert C. The global allergy and asthma European network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42. https://doi.org/10.4193/rhin17.255
Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121(12):2672-2678. https://doi.org/10.1002/lary.21847
De Conde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555. https://doi.org/10.1002/lary.26391
Calus L, Van Bruaene N, Bosteels C, Dejonckheere S, Van Zele T, Holtappels G, Bachert C, Gevaert P. Twelve-year follow- up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clinical and Translational Allergy. 2019;9(1):30. https://doi.org/10.1186/s13601-019-0269-4
Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA, Schlosser RJ. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. International Forum of Allergy and Rhinology. 2020;10(2):199-207. https://doi.org/10.1002/alr.22487
Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ. Outcomes of modifed endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. International Forum of Allergy and Rhinology. 2016;6(8):820-825. https://doi.org/10.1002/alr.21739
Lou H, Zhang N, Bachert C, Zhang L. Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. International Forum of Allergy and Rhinology. 2018;8(11):1218-1225. https://doi.org/10.1002/alr.22214
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, Förster-Ruhrmann U, Kowalski ML, Olszewska-Ziąber A, Holtappels G, De Ruyck N, Wang X, Van Drunen C, Mullol J, Hellings P, Hox V, Toskala E, Scadding G, Lund V, Zhang L, Fokkens W, Bachert C. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology. 2016;137(5):1449-1456.e4. https://doi.org/10.1016/j.jaci.2015.12.1324
Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang N. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications. Journal of Allergy and Clinical Immunology. In Practice. 2020;8(5):1514-1519. https://doi.org/10.1016/j.jaip.2020.03.007
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha An- selmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O’Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Or- landi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Snidvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(29):1-464. https://doi.org/10.4193/Rhin20.600
De Filippo M, Votto M, Licari A, Pagella F, Benazzo M, Ciprandi G, Marseglia GL. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Review of Respiratory Medicine. 2021;15(10):1303-1316. https://doi.org/10.1080/17476348.2021.1937132
Blauvelt A, Gooderham M, Foley P, Griffiths CEM, Cather JC, de Bruin-Weller M, Zhu X, Akinlade B, Graham NMH, Pirozzi G, Shumel B. P67: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. International Medical Journal. 2017;47:25. https://doi.org/10.1111/imj.67_13578
Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate Dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Advances in Therapy. 2018;35(5):737-748. https://doi.org/10.1007/s12325-018-0702-4
Koski RR, Hill L, Taavola K. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps. Journal of Pharmacy and Technology. 2022;38(5):289-296. https://doi.org/10.1177/87551225221105749
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TN, Cervin AU, Maspero JF, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens W, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannet LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. https://doi.org/10.1016/S0140-6736(19)31881-1
Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Annals of Allergy, Asthma and Immunology. 2021;126(5):584-592. https://doi.org/10.1016/j.anai.2021.01.012
Hopkins C, Wagenmann M, Bachert C, Desrosiers M, Han JK, Hellings PW, Lee SE, Msihid J, BChir AR MB, Rowe P, Amin N, Deniz Y, Ortiz B, Mannet LP, Rout R. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. International Forum of Allergy and Rhinology. 2021;11(7):1087-1101. https://doi.org/10.1002/alr.22780
Boiko NV, Stagnieva IV, Lodochkina OE, Kiselev VV, Bykova VV. Efficacy of reslizumab in the treatment of asthma and comorbid chronic rhinosinusitis with polyps. Vestnik sovremennoj klinicheskoi meditsiny. 2021;14(6):22-27. (In Russ.). https://doi.org/10.20969/VSKM.2021.14(6).22-27
Fokkens WJ, Lund V, C. Bachert C, Mullol J, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, Hellings PW. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319. https://doi.org/10.1111/all.13875
Kim J, Naclerio R. Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date. Therapeutics and Clinical Risk Management. 2020;16:31-37.
Boiko NV, Lodochkina OE, Kit MM, Kuleshova VG, Nedashkovskaya NG. Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma. Vestnik otorinolaringologii. 2021;86(2):43-48. (In Russ.). https://doi.org/10.17116/otorino20218602143
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(2):589-596.e3. https://doi.org/10.1016/j.jaip.2018.08.021
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22 — item Sinonasal Outcome Test. Clinical Otolaryngology. 2009;34(5):447-454. https://doi.org/10.1111/j.1749-4486.2009.01995.x
Kurbatova NV. Paket STATISTICA, analiz dannykh i vyyavlenie zakonomernostei. TsVVR; 2002. (In Russ.).
Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. The Journal of Allergy and Clinical Immunology: In Practice. 2015;3(2):167-174. https://doi.org/10.1016/j.jaip.2015.01.013
Kariyawasam H, James LK, Gane SB. Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps. Drug Design, Development and Therapy. 2020;14:1757-1769. https://doi.org/10.2147/dddt.s243053

Close metadata